3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Supranuclear Palsy, Progressive: new trials by email Literature Review of Supranuclear Palsy, Progressive trials Research Report on Supranuclear Palsy, Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) ABBV-8E12, Placebo solution for IV infusion on Day 15 - Progressive Supranuclear Palsy (PSP) | Phase 2 | Terminated | AbbVie | 142 | 2018-01-24 | 2021-02-03 |
| Study of BIIB092 in Participants With Progressive Supranuclear Palsy BIIB092, Placebo - Supranuclear Palsy, Progressive | Phase 2 | Terminated | Biogen | 490 | 2017-06-01 | 2020-12-21 |
| A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) Placebo, ABBV-8E12 - Progressive Supranuclear Palsy | Phase 2 | Terminated | AbbVie | 378 | 2016-12-12 | 2021-02-03 |
Tauopathies (2)
Basal Ganglia Diseases (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Cranial Nerve Diseases (3) · Eye Diseases (3) · Movement Disorders (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Neurologic Manifestations (3) · Ocular Motility Disorders (3) · Ophthalmoplegia (3) · Paralysis (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Tauopathies (1)
tilavonemab (2) · gosuranemab (1)
Australia (3) · Canada (3) · Italy (3) · Japan (3) · United States (3) · France (2) · Germany (2) · Spain (2) · Austria (1) · Greece (1) · Russia (1) · South Korea (1) · United Kingdom (1)
PMID 33609476, PMID 34385707, PMID 34736158, PMID 38825840
2016 (2), 2017 (1)